Kappa and delta opioid receptors: Potential therapeutic targets
摘要截稿:
全文截稿: 2024-05-31
影响因子: 2.519
期刊难度:
CCF分类: 无
中科院JCR分区:
• 大类 : 心理学 - 4区
• 小类 : 行为科学 - 4区
• 小类 : 神经科学 - 4区
• 小类 : 药学 - 4区
Overview
A focus on current and potential therapeutic targets for ligands that act on KOR and/or DOR. It will include basic and translational research, as well as a summary of human research.Guest editors:
Sari Izenwasser, Department of Psychiatry & Behavioral Sciences,University of Miami Miller School of Medicine,Miami, FL 33136Email: sizenwasser@med.miami.edu
Special issue information:
The pharmacological, physiological, behavioral, and biochemical effects of exogenous opioids, including heroin, fentanyl, and prescription opioids, have been extensively investigated, leading to the discovery of the endogenous opioid system consisting of diverse but related endogenous opioid peptides as well as their targets, the Mu, Kappa, and Delta opioid receptors (MOR, KOR, and DOR, respectively) (along with the closely homologous opioid-like receptor ORL-1). As MOR is the primary target of compounds which potently alleviate pain and cause euphoria and excessive use which can lead to addiction, physical dependence, and respiratory depression, it has been studied much more extensively than KOR and DOR.
The development of selective ligands has been crucial for investigations of the commonalities and differences in the function of these receptor systems, as well as on the roles KOR and DOR play in endogenous regulation of behaviors and physiology. Drug discovery efforts continue to play an important role in extending our understanding of the pharmacology and biochemistry of these receptors. Additional tools have since emerged to allow for specific investigation of the roles these receptors may play in diverse physiological processes and medical treatment. Such tools include selective PET ligands, gene knockout/knockin studies, and opto- and chemo-genetic manipulation in animal models, among others. Both DOR and KOR agonists have effectiveness as analgesics in some animal models of pain. Further, ligands for both of these receptors are under investigation for their effectiveness in animal models of substance use disorders, depression, and anxiety, among other therapeutic areas.
This special issue will therefore focus on current and potential therapeutic targets for ligands that act on KOR and/or DOR. It will include basic and translational research, as well as a summary of human research.
Manuscript submission information:
The Journal’s submission system is open for receiving submissions to our Special Issue.
To ensure that all manuscripts are correctly identified for inclusion into the special issue you are editing, it is important that authors select, “VSI: Kappa & delta opioid receptors" when they reach the “Article Type” step in the submission process.
Please submit your manuscript via EM submission portal before 31st May 2024.
For any inquiries about the appropriateness of contribution topics, please contact the corresponding Guest Editor, Dr. Sari Izenwasser at sizenwasser@med.miami.edu
All the submissions deemed suitable to be sent for peer review will be reviewed by at least two independent reviewers. Upon its editorial acceptance, your article will go into production immediately. It will be published in the latest regular issue, while be presented on the specific Special Issue webpage simultaneously. In regular issues, Special Issue articles will be clearly marked and branded.
Please ensure you read the Guide for Authors before writing your manuscript. The Guide for Authors and link to submit your manuscript is available on the Journal’s homepage here
Submission Deadline is 31st May 2024